Tradjenta Contract Sales Force (238 Postings)

Quote


















Anonymous said:
No. That would violate the Restraining order.
Click to expand...

No it would not. As long as sales forces are separate, that is what Amylin is seeking. Besides, this sales force of 238 rep sales force is not big enough to deliver the kinds of reach and frequency numbers we have promised to BI.

Byetta is a dying drug, I am tired of my endos telling me that their patients prefer one shot a day over two. Hard to argue that.
 


















Anonymous said:
No it would not. As long as sales forces are separate, that is what Amylin is seeking. Besides, this sales force of 238 rep sales force is not big enough to deliver the kinds of reach and frequency numbers we have promised to BI.

Byetta is a dying drug, I am tired of my endos telling me that their patients prefer one shot a day over two. Hard to argue that.
Click to expand...


Byetta is dying but we are holding our breath waiting for once a week. Until then Diabetes will be divided and I bet MSK gets Tradjenta. What the hell are they selling anyway. The focus reps already call on Endos. Nuero just got the new testosterone so they are saved a little.
 






Anonymous said:
Byetta is dying but we are holding our breath waiting for once a week. Until then Diabetes will be divided and I bet MSK gets Tradjenta. What the hell are they selling anyway. The focus reps already call on Endos. Nuero just got the new testosterone so they are saved a little.
Click to expand...

Im betting Tradjenta dies before Byetta. Seriously though! Which one of our great leaders dropped the ball on this one? We now have a subpar 3rd to market drug that does nothing different than Januvia or Onglyza. Our entire sales platform is around our $10/month value card which Onglyza has had out for a while now. Even the docs are saying that a little science would be nice but no, our leave behinds have 2 pages of value card info and a tiny bit of science. This drug was dead before we even trained on it.
 






Anonymous said:
Im betting Tradjenta dies before Byetta. Seriously though! Which one of our great leaders dropped the ball on this one? We now have a subpar 3rd to market drug that does nothing different than Januvia or Onglyza. Our entire sales platform is around our $10/month value card which Onglyza has had out for a while now. Even the docs are saying that a little science would be nice but no, our leave behinds have 2 pages of value card info and a tiny bit of science. This drug was dead before we even trained on it.
Click to expand...

I work at BI and that's pretty standard here. We've launched several drugs with nothing more than a PI so I don't expect much these days. Having a savings card at launch (well sort of having it since we've run out already) is a vast improvement. However, we haven't heard a damn word from our corporate management since launch other than to say Lilly isn't selling Tradjenta and then the message to say Lilly is selling it. Nothing more that from our fearless leader. I've come to the conclusion that all pharma companies are managed by a bunch of monkeys. Watching our VP or yours having the "who can piss the farthest contest" at the launch meeting was amusing though.
 






Top Bottom
Back
Quote